Paradoxically, loss of SMAD4 expression has been described to occur typically in later stages of the adenoma to carcinoma sequence, where it is associated with elevated signaling by the TGF-β family, as well as a mesenchymal CRC phenotype, high amounts of stroma, and poor prognosis [10, 42]. Here, SMAD4 is linked to carcinoma.